Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Karin Cerri"'
Autor:
Jayne, Smith-Palmer, Karin, Cerri, Urbano, Sbarigia, Eric K H, Chan, Richard F, Pollock, William J, Valentine, Kristien, Bonroy
Publikováno v:
Patient Related Outcome Measures
Background People with chronic infectious diseases such as hepatitis B can face stigma, which can influence everyday life as well as willingness to engage with medical professionals or disclose disease status. A systematic literature review was perfo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::33b8c92fb82b0237bb6ff0091fa5eff1
https://pubmed.ncbi.nlm.nih.gov/32214859
https://pubmed.ncbi.nlm.nih.gov/32214859
Publikováno v:
Hepatology research : the official journal of the Japan Society of Hepatology. 45(10)
Simeprevir (SMV) is an oral, once-daily protease inhibitor for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. In phase II/III randomized controlled trials (RCT) conducted in Japan, SMV, in combination with peginterferon-α and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2ee1fd3673d18413162fb0c0a4f8ba81
https://pubmed.ncbi.nlm.nih.gov/25559771
https://pubmed.ncbi.nlm.nih.gov/25559771
Autor:
Mats Björeman, Isidro Villanueva, Michele Intorcia, Veronique Halkin, Juan Luis Steegmann, Carine Cohen, Enrica Morra, Mauricette Michallet, Cosimo Paga, Gert J. Ossenkoppele, Thomas Kühr, Karin Cerri, David Marin Costa, Gregor Verhoef
Publikováno v:
Blood. 110:1959-1959
Current recommendations for patients with CML (Baccarani M, et al. Blood2006;108:1809–20) advocate regular treatment response monitoring, including evaluation of: cytogenetic response (CyR) at least every 6 months until complete CyR is achieved, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c193c7de72cb489a27ddca0673e941f
https://doi.org/10.1182/blood.v110.11.1959.1959
https://doi.org/10.1182/blood.v110.11.1959.1959
Autor:
Claire Cropet, Gregor Verhoef, Enrica Morra, Mats Björeman, Laurence Van Bree, Juan Luis Steegmann, Isidro Villanueva, Karin Cerri, David Marin Costa, Muriel Sterckx, Mauricette Michallet, Gert J. Ossenkoppele, Thomas Kühr
Publikováno v:
Blood. 110:1951-1951
Imatinib is widely used for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), and is associated with improved response rates in these patients. However, the management of patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88a206395d6926353d6b82a1cd166b3f
https://doi.org/10.1182/blood.v110.11.1951.1951
https://doi.org/10.1182/blood.v110.11.1951.1951